Make 2nds Count is aware that founder Lisa Fleming has spoken on social media about legal action she has brought against the charity. The charity will not comment about the active tribunal other than to confirm that we refute all aspects of the claim ..read more

Sacituzumab govitecan-hziy (known by the trade name TRODELVY®) was approved for NHS usage in 2022 for secondary TNBC patients, who have had two or more systemic therapies (such as chemotherapies), with at least one of these being for advanced disease. TRODELVY® was approved for this demographic of secondary TNBC patients because a phase 3 clinical trial (known as the ASCENT trial) showed positive patient outcomes ..read more

Can you tell me a little about yourself? I'm 25 years old and live in Newcastle Upon Tyne with my boyfriend Jake and our German Shepherd Luna ..read more

The Food and Drug Administration (FDA) is responsible for approving drugs for disease treatment in America. Typically, before a new cancer drug is approved for usage in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), which has a separate approval process, the drug will initially get approved for usage in America by the FDA first ..read more

The government has scrapped the specific NHS England 10-year cancer strategy for a new blended 5-year Major Conditions Strategy. England’s health and social care secretary, Steve Barclay, told the House of Commons on 24 January that the Department of Health and Social Care is currently developing a new 5-year Major Conditions Strategy that will tackle the major conditions that contribute to the burden of disease in England ..read more

The Northern Ireland Cancer Registry at Queen's University Belfast will conduct this study after receiving funding from the charity Cancer Focus NI. This is the first study of its kind and by gathering information on the number of patients living with secondary breast cancer in NI it will help with the future planning of services that can support the needs of patients ..read more

SBC & Me Date of diagnosis? 2021 Current treatment line ..read more

The Make 2nds Count team, trustees and volunteers attended the Edinburgh Breast Cancer Special Symposium (EBCSS) on Saturday 25th February.The event hasn't been held for several years due to COVID, so there was a lot of interest now that it's finally back face to face. The biennial event brings together scientists, healthcare providers and patients to discuss the latest thinking in breast cancer ..read more

At the end of January, ORSERDU™ (elacestrant) received Food and Drug Administration (FDA) approval as a new oral treatment for ER+ HER2- metastatic breast cancer in the United States. Endocrine therapy (also known as hormone therapy), with either aromatase inhibitors (AI) or fulvestrant, plus a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor is the recommended first-line standard-of-care for metastatic ER+ HER2- breast cancer ..read more

When diagnosed with secondary breast cancer, all of the medical terminologies can be very overwhelming. This three part series of posts will tell you a little bit more about the main classifications of secondary breast cancer that are used to direct medical treatments ..read more